XenTech

XenTech is a CRO specialized in Patient-Derived Xenograft (PDX) models, a human tumor-based in vivo approach for accurate and highly predictive testing/profiling of many anti-cancer therapy modalities: ADCs, PARPI and DDRi, TKIs,... .

The panel of 200+ deeply characterized models closely replicates the biological features of human tumors and covers the molecular diversity of clinical diseases for breast, prostate and many others cancer indications. All our studies are governed by a high-standard system of quality management and provide robust data for confident progression to clinical phases.

Xentech also proposes PDX Derived cellulars models derived from PDX in vivo models for in vitro testing of anti-cancer drug candidates.